Completed PHASE2 INTERVENTIONAL 2-arm NCT00766324

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer

Sponsor: Nerviano Medical Sciences

Conditions Metastatic Hormone Refractory Prostate Cancer

Interventions PHA-739358

Updated 7 times since 2017 Last updated: May 13, 2014 Started: Sep 30, 2007 Primary completion: Mar 31, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Hormone Refractory Prostate Cancer, this trial is completed. The trial is conducted by Nerviano Medical Sciences and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nerviano Medical Sciences

Data source: Nerviano Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nerviano, Italy